Get started
Award

Genetics of Response to Canagliflozin

Description: There is considerable variation among responses of individual diabetic patients to the same antidiabetic therapy. The proposed study aims to identify biomarkers to predict how an individual diabetic patient will respond to the sodium-glucose cotransporter-2 inhibitor class of antidiabetic drugs. Availability of predictive biomarkers would enable physicians to prescribe therapies for each individual patient based on predictors of beneficial response and susceptibility to adverse effects.
Funding type: research
Funder scheme: R01
Start date: 2018-07-01
End date: 2024-04-30
Investigator: AMBER L BEITELSHEES
Institution: UNIVERSITY OF MARYLAND BALTIMORE
Field: Medicine
Funded outputs count: 14
Funder award ID: R01DK118942
OpenAlex ID: G2875333222
Classical homeostatic physiology sheds light on vitamin D controversies
2026 · Simeon I. Taylor, Zhinous S. Yazdi · Trends in Endocrinology and Metabolism
Comment on Griffin et al. Use of SGLT2i Versus DPP-4i as an Add-on Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery): A Cohort Study in Veterans With Diabetes. Diabetes Care 2025;48:361–370
2025 · Sayna Bagheri, Simeon I. Taylor · Diabetes Care · 1
PDF
Evolving Approaches for Pharmacological Therapy of Obesity
2024 · Ariana M. Chao, Simeon Taylor, et al. · The Annual Review of Pharmacology and Toxicology · 22
Value of Vitamin D Metabolite Ratios in 3 Patients as Diagnostic Criteria to Assess Vitamin D Status
2024 · Zhinous Shahidzadeh Yazdi, Elizabeth A Streeten, et al. · JCEM Case Reports · 1
Critical Role for 24-Hydroxylation in Homeostatic Regulation of Vitamin D Metabolism
2024 · Zhinous Shahidzadeh Yazdi, Elizabeth A. Streeten, et al. · The Journal of Clinical Endocrinology & Metabolism · 11
PDF
Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH
2023 · Zhinous Shahidzadeh Yazdi, Elizabeth A. Streeten, et al. · The Journal of Clinical Endocrinology & Metabolism · 5
PDF
Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker
2023 · Simeon I. Taylor, Hua‐Ren Cherng, et al. · Diabetes Obesity and Metabolism · 4
PDF
Individualized Glycemic Goals for Older Adults Are a Moving Target
2022 · Scott J. Pilla, Zhinous Shahidzadeh Yazdi, et al. · Diabetes Care · 11
The trans-ancestral genomic architecture of glycemic traits
2021 · Ji Chen, Cassandra N. Spracklen, et al. · Nature Genetics · 794
PDF
Pharmacological treatment of hyperglycemia in type 2 diabetes
2021 · Simeon I. Taylor, Zhinous Shahidzadeh Yazdi, et al. · Journal of Clinical Investigation · 246
YIPF5 mutations cause neonatal diabetes and microcephaly: progress for precision medicine and mechanistic understanding
2020 · Toni I. Pollin, Simeon I. Taylor · Journal of Clinical Investigation · 7
PDF
The High Cost of Diabetes Drugs: Disparate Impact on the Most Vulnerable Patients
2020 · Simeon I. Taylor · Diabetes Care · 66
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
2019 · Simeon I Taylor, Jenny E Blau, et al. · The Lancet Diabetes & Endocrinology · 124
Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
2019 · Amber L. Beitelshees, Bruce R. Leslie, et al. · Diabetes · 70
Adverse effects of SGLT2 inhibitors on bone health
2018 · Jenny E. Blau, Simeon I. Taylor · Nature Reviews Nephrology · 75
Year
Topic